Genentech, Inc.

Weiguang Mao

Paul Polakis

Leonard G Presta

Napoleone Ferrara

Ellen Filvaroff

Andrew G Polson

Camellia W Adams

Max L Tejada

Yan Wu

Wei-Ching Liang

Jagath Reddy Junutula

Jo-Anne Hongo

Ron Firestein

Rajesh Vij

Leonard Presta

The invention provides anti-LgR5 antibodies and methods of using the same.

Anti-LGR5 antibodies and uses thereof

The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.

Anti-LGR5 antibodies and immunoconjugates

Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I:Ab-(L-D)&#x2003;&#x2003;I

Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates

Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.

Humanized anti-TGF-beta antibodies

The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.

Anti-EphB2 antibodies and methods using same

Growing community of inventors

San Mateo, CA, United States of America

Weiguang Mao